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Abstract
Background: Providing healthcare professionals with health surveillance data aims to support professional and
organisational behaviour change. The UK Five Year Antimicrobial Resistance (AMR) Strategy 2013 to 2018 identified
better access to and use of surveillance data as a key component. Our aim was to determine the extent to which
data on antimicrobial use and resistance met the perceived needs of health care professionals and policy-makers at
national, regional and local levels, and how provision could be improved.
Methods: We conducted 41 semi-structured interviews with national policy makers in the four Devolved
Administrations and 71 interviews with health care professionals in six locations across the United Kingdom
selected to achieve maximum variation in terms of population and health system characteristics. Transcripts were
analysed thematically using a mix of a priori reasoning guided by the main topics in the interview guide together
with themes emerging inductively from the data. Views were considered at three levels - primary care, secondary
care and national - and in terms of availability of data, current uses, benefits, gaps and potential improvements.
Results: Respondents described a range of uses for prescribing and resistance data. The principal gaps identified
were prescribing in private practice, internet prescribing and secondary care (where some hospitals did not have
electronic prescribing systems). Some respondents under-estimated the range of data available. There was a
perception that the responsibility for collecting and analysing data often rests with a few individuals who may lack
sufficient time and appropriate skills.
Conclusions: There is a need to raise awareness of data availability and the potential value of these data, and to
ensure that data systems are more accessible. Any skills gap at local level in how to process and use data needs to
be addressed. This requires an identification of the best methods to improve support and education relating to
AMR data systems.
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Background
It is generally believed that the availability of good qual-
ity routine performance data is essential to achieve posi-
tive change in professional and organisational behaviour.
In the case of tackling antimicrobial resistance (AMR),
the availability of reliable and timely information is asso-
ciated with a reduction in patient mortality and morbid-
ity [1]. The focus of surveillance in the AMR context is
threefold: the use of antimicrobial drugs (predominantly
antibiotics); the incidence of reduced susceptibility of or-
ganisms to antibiotics (resistance); and the incidence of
antimicrobial resistant infections. The aim of notifying
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prescribers and other interested parties as soon as pos-
sible is to improve the appropriateness of therapy for
treating resistant pathogens, to deal with outbreaks ef-
fectively and to allow strategies to be formulated to re-
duce or prevent any further development of resistance
[2].
The importance of such data was recognised in the
UK in the Five Year Antimicrobial Resistance Strategy
2013 to 2018 [3], which identified “better access to and
use of surveillance data” as one of its seven key areas for
action. Considerable investment was made in surveil-
lance systems over the life-course of the Strategy [4, 5].
In England, during the first year of the Strategy, a sur-
veillance programme for antimicrobial utilisation and re-
sistance (ESPAUR) was implemented. Its first report in
2014 provided data on antibiotic use (both in primary
and secondary care) and on resistance to antibiotics.
The report provided a baseline for monitoring subse-
quent changes [4]. Other developments in England were
the introduction of the Second Generation Surveillance
System for reporting of infectious diseases and anti-
microbial resistance in humans, and an electronic system
for reporting infections with carbapenamase-producing
organisms [5]. Users of this information are wide-
ranging and include prescribers, microbiologists, infec-
tion control practitioners, purchasers of health care,
regulatory bodies, public health authorities and pharma-
ceutical companies [2]. The Devolved Administrations in
the UK are working towards achieving the systems avail-
able in England. The Northern Ireland Public Health
Agency produced its first report on the surveillance of
antimicrobial use and resistance in Northern Ireland in
2017 [6] and sends general practitioner (GP) practices
individualised “Compass” Reports that describe their
prescribing levels relative to neighbouring practices and
the Province. Wales produces a range of annual reports
alongside point prevalence surveys. Finally, Scotland
produces a single annual report for animal and human
health, and has made considerable recent progress in de-
veloping an integrated data platform that brings together
infection-related data from a number of datasets [7].
However, progress appears to have paused currently,
and there are no plans to make the platform publicly ac-
cessible. A quality improvement platform, Discovery, has
some resistance and use measures available to
authorised users across Scotland [8].
Our aim was to determine the extent to which existing
antimicrobial utilisation and resistance data meet the
perceived needs of health care professionals at national,
regional and local levels, and how provision could be im-
proved to contribute to the framing of the new UK
AMR National Action Plan 2019–2024 [9] published in
January 2019. Our objectives were to understand the
views of a wide range of relevant practitioners and
managers at local, regional and national level. This was
part of a larger study investigating how data had been
used, not only in human health care but in animal health
as well, to effect changes in behaviour and their impacts
[10].
Methods
The study employed semi-structured interviews with
staff at national level in each part of the UK (England,
Scotland, Wales and Northern Ireland) and at a local
level in six case study sites across the UK. Respondents
at national level comprised policy-makers from relevant
UK Government Departments (including Department of
Health and Social Care and Public Health England and
the Department of Environment, Food and Rural Affairs)
and in the Devolved Administrations (including mem-
bers of the Scottish Antimicrobial Prescribing Group;
Health Protection Scotland; Public Health Wales; North-
ern Ireland Public Health Agency; Northern Ireland
Strategic Antimicrobial Resistance and Healthcare-
associated Infection [SAMRHAI] group and the North-
ern Ireland Health and Social Care Board), members of
the High Level Steering Group responsible for oversee-
ing delivery of the Strategy, and experts in the field of
human and animal health surveillance.
The sampling strategy for the case study sites
employed a maximum variation design taking into ac-
count a range of characteristics that might influence ex-
periences and views of respondents at local level. These
included antibiotic prescribing levels, deprivation levels,
urban/rural nature and agricultural activities. In recogni-
tion of the wide range of professionals utilising such
data, the local sampling strategy included not only pri-
mary and secondary care medical prescribers and users
of resistance data but also local commissioners of ser-
vices (based in Clinical Commissioning Groups [CCGs]
in England and the equivalent organisations in Wales,
Scotland and Northern Ireland).
The interviews broadly followed a topic guide and cov-
ered many aspects of the UK AMR Strategy relevant to
the use of antimicrobial utilisation and resistance data,
with the topic guide being tailored to the role of the
interviewee (Supplementary file 1 and 2). The inter-
viewers tested and refined the topic guide as a group,
and initial interviews of each team member were ob-
served by EE to ensure a consistent approach. The inter-
viewers were experienced qualitative researchers (from
non-medical or microbiological sciences backgrounds)
working in the field of health services research and
health policy evaluation. The interviews took place be-
tween March 2017 and June 2018, and lasted an average
of 60 min. Interviews were conducted face-to-face or
over the telephone, audio recorded and transcribed
using an external transcription service.
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As a commissioned evaluation of the implementation
of a government strategy, we adopted a ‘realist’ or ‘subtle
realist’ position, whereby we acknowledge the presence
of an external independent world “out there” (for ex-
ample biological mechanisms), whilst also accepting that
these phenomena can ultimately only be understood
using our interpretation of them [11]. Interview data
were analysed thematically. First level coding was based
on themes from the research questions and interview
topic guides, and other themes identified inductively
from the data. The research team independently read
and coded transcripts, and as a group discussed initial
themes before agreeing main themes and sub-themes for
further analysis, consistent with a ‘constant comparison’
approach to qualitative data interpretation [12]. Inter-
view transcripts were coded using NVivo 11. Members
of the research team interrogated the data repeatedly
both within and across the cases in order to understand
key issues.
The findings were anonymised to protect the identity
of informants. However, quotes include a reference to
the informant’s role to provide a context for the views
expressed.
Significant differences between prescribing, Infection
Prevention and Control (IPC), and resistance data,
meant that interview data were analysed separately for
antibiotic use and for resistance. The views of respon-
dents at the three principal levels in human health - pri-
mary care, secondary care and national - were also
considered separately. Respondents’ views were consid-
ered in terms of several a priori themes: availability of
data; current uses; perceived problems and gaps; bene-
fits; and suggested improvements.
Results
A total of 41 interviews were conducted with national
level staff and 71 with informants in the six case study
areas: West Norfolk (n = 14: from a CCG, primary care,
secondary care and local authority); Blackburn with Dar-
wen (n = 12: from a CCG, primary care, secondary care
and local authority); Derry/ Londonderry (n = 13: from
primary care, secondary care and the Health and Social
Care Board); Betsi Cadwaladr (n = 12: from primary care,
secondary care and a Health Board); Glasgow (n = 11:
from primary care, secondary care and a Health Board)
and Camden (n = 9: from a CCG, primary care, second-
ary care and local authority).
Prescribing and resistance data are predominantly
used to monitor and improve prescribing practice as
well as to prevent outbreaks of infections. Respondents
identified gaps in the current provision of data, and
made several suggestions for how current provision
could be improved, in part, by taking into consideration
the local context and the workforce needed to collect
and analyse the data. The following sections describe
these findings in greater detail.
Prescribing data
Primary care
Respondents identified several uses for prescribing data
in primary care; first, assisting practitioners by enabling
them to reflect on their current prescribing to improve
their practice, with one respondent expressing the view
that giving data to practitioners could be a powerful way
of illustrating to individuals who overprescribe how they
compare with their peers:
“I actually went to [an in-house] practice meeting
and they’d just run it off [prescribing data] and
they’d handed it out. There was a GP there and they
just said, ‘You know what? I have absolutely no idea
why I prescribe more antibiotics than anyone else.’
She was just, kind of, horrified because she said,
‘Why would I ever know that, because I assume that
I’m only giving them when they’re needed? You
know, people come in and they give talks on anti-
microbial stewardship and I’ve always just thought
well, you know, they’re not talking about this. I’m
absolutely bad,’ and she was really open and honest
about it. She just said, ‘I’m just horrified at this
data.’ You know, that was the most powerful thing
that I’ve ever seen with it was” (Antimicrobial
Pharmacist)
Second, local commissioners of health services sug-
gested that data could identify issues at practice level
that needed to be addressed, as well as to advise GPs
on what they should be prescribing. They also re-
ported using prescribing data to compare the per-
formance of GP practices over time, between
practices and between areas. However, the process of
identifying high-prescribing practices based on the
proportion of their prescribed antibiotics that were in
the “4 Cs” (clindamycin, cephalosporins, co-amoxiclav
and ciprofloxacin) group of drugs often targeted in
stewardship campaigns, was seen by one GP as poten-
tially unfair on practices with fewer registered pa-
tients, as a small number of patients with complex
medical conditions could be sufficient to identify the
practice as a high prescriber. One respondent felt that
this process might lead some practitioners to under-
prescribe antibiotics when they were clinically
indicated:
“ … I do recall a GP appraiser friend that was de-
scribing how she appraised a doctor; he said, ‘oh, I
am the lowest prescriber of antibiotics in entire [geo-
graphic location]’, and was extremely proud, and
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didn’t realise that probably being the lowest pre-
scriber might mean that he didn’t prescribe enough,
that some patients were maybe being denied it
whenever it was clinically appropriate to give it to
them … ” (GP Medical Advisor)
Although the benefits of having access to prescribing
data in primary care were expressed in all of the case
study sites, as well as in the interviews conducted at na-
tional level, local interviewees in the four countries felt
that the formatting and presentation of the data could
be improved:
“I think one of the most powerful tools we have is the
data but I guess it’s about not just sending them a
spreadsheet and expecting them to interpret it them-
selves … ”. (Antimicrobial Pharmacist)
A perceived gap in the data was that commissioners
were unable to access the indications for individual pre-
scriptions of antibiotics because they had only limited
information on the patients’ characteristics. For example,
the ePACT2 system in England does not provide the in-
dications for the prescription.
Respondents suggested the following six potential im-
provements to surveillance data on prescribing:
 Collecting data at more frequent intervals to take
into account seasonal variations;
 Collecting data from a wider range of prescribers to
enable non-medical prescribers (for example, nurse
practitioners) to compare their prescribing against
their peers;
 The provision of data in a more accessible format
(for example, by adopting a ‘traffic-light’ system for
the identification of prescribing outliers);
 Adopting an approach that is tailored to local
circumstances through highlighting both the areas
where more action is needed and the positive
changes that have occurred locally, as argued by this
respondent:
“ … for example I’d like to know what percentage of
the antibiotic prescribing that is going on in the com-
munity for UTIs [Urinary Tract Infections], that sort
of breakdown, because it would help target, because
we are doing lots of targeted interventions. Like we’ve
recently come up with the hydration policy for nurs-
ing home residents where they’re encouraged to drink
more so that they prevent … they stop them getting
UTIs and needing antibiotics and hospital admis-
sions, so those sort of initiatives. But in terms of data
I think it’s really lacking.” (Consultant
Microbiologist)
 Linking prescribing volume and outcomes (such as
secondary complications) in the data that are shared
with prescribers in primary care, as well as capturing
the number of patients experiencing side-effects of
antibiotics (such as nausea) or the “numbers needed
to harm” in data presented to clinicians.
Secondary care
In hospitals, prescribing data were reported to be used
as part of performance management systems within divi-
sions and departments. It was felt that the production of
“league tables” for prescribers within hospitals was im-
portant for motivating change in behaviour, as doctors
were described as naturally competitive, and would not
want to be at the bottom of any performance table.
However, one respondent cautioned that prescribing
data needed to be accurate if they were used to measure
performance:
“The big danger with producing surveillance data is
that it’d better be accurate, otherwise you’re feeding
rubbish centrally, which will produce a rubbish out-
put that people will then be judged on.” (Lead Con-
sultant Microbiologist)
Respondents also identified limitations of current pre-
scribing data systems. For instance, in some areas, re-
spondents felt that annual prescribing surveys were not
frequent enough. In some hospitals, it was still not pos-
sible to obtain prescribing levels by ward or by pre-
scriber, as a result of paper-based prescribing requests,
with the only available data being the amount of antibi-
otics issued in every ward on a weekly basis. The ab-
sence of electronic prescribing (e-prescribing) in some
hospitals also precluded the ability to target stewardship
interventions at individual prescribers who had not
changed their prescribing following the introduction of
guidelines. It also made it harder to detect and respond
rapidly to issues that might arise as a result of changes
in prescribing volumes, for example, side effects of medi-
cations, since these figures were currently about one
month out of date. Further, it meant that the data often
required considerable manipulation before they could be
used, due to the reported unavailability of software that
can process data and present them in a format that is ac-
cessible to users in secondary care, as explained by this
respondent:
“I guess we don't have a hospital pharmacy prescrib-
ing system … And I guess the challenge there is it
[usage data] needs significant data manipulation in
order to get something meaning [ful] because you've
got to make adjustments for daily divided doses and
so forth … You'd make that adjustment, manipulate
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it and it would then give you something meaningful.
Whether the usage is high, medium, low.” (Hospital
Pharmacist)
One respondent noted a reliance on scarce in-house staff
who have skills in processing data and presenting them
in an accessible format, expressing the concern that if
they moved on to another role, there could be a skills
gap that would be challenging to fill.
Additionally, the time consumed in data collection
(partly due to existing IT infrastructure limitations),
combined with the difficulty of collecting relevant data,
raised questions about the opportunity costs of collect-
ing the data as explained by this interviewee:
“We’ve been presented with a form that has 20-
something questions on it, and the questions relate
to antimicrobial use in the last 28 days. Did some-
body have a catheter at any stage in the last 28
days, and various other questions which relate to the
patients, but not to how the patient is today, and
how on earth am I going to, with any reliability, de-
termine whether someone did or didn’t have a cath-
eter three weeks ago, on a different ward, on a
different admission?” (Lead Consultant
Microbiologist)
Another concern related to the process of producing sur-
veillance reports, which could potentially create friction
among colleagues with the risk that one group of clinicians
would accuse the other of “policing” their colleagues.
Some interviews revealed a lack of awareness of some
of the data already available. A non-executive member
of a National Health Service (NHS) Trust hospital board
expressed the desire for a tool to benchmark the hospi-
tal’s prescribing levels against other hospitals in England,
unaware that this is available through the Fingertips Por-
tal [13].
Introducing e-prescribing throughout secondary care
was often identified as a priority for the future, whilst ac-
knowledging that persuading the NHS and the Govern-
ment to invest in such systems would be a major
challenge. Respondents described their expectations of
what an e-prescribing system would deliver, suggesting,
for example, that such a system would permit the exam-
ination of prescribing levels by ward and prescriber. The
view was also held that being able to link prescribing
with diagnoses and the ability to compare trends on the
same ward over time without the threat of punitive ac-
tions from managers or regulators, would stimulate
change, as this interviewee explained:
“ … if I could say, okay, in respiratory over the win-
ter months, on average we have 80% of patients on
IV antibiotics; in the summer we’ve got 60% - oh,
but this month we’ve only got 20% - that would be
like, well, what’s different? So, a prompt to go and
look at that.” (Chief Pharmacist)
One respondent, however, also pointed out that e-
prescribing would not eliminate the difficulties associ-
ated with data collection, as in some hospitals where
these systems had been introduced, there continued to
be problems with some prescribers still not stating the
indications for their prescriptions.
National audits of antimicrobial usage were the second
need reported by respondents, as these would enable
hospital staff to compare themselves with similar hospi-
tals across the country and with national benchmarks.
National level
Similar to their use in primary and secondary care, pre-
scribing data are used at national level for performance
management. For example, NHS England uses prescrib-
ing information to “red flag” CCGs that over-prescribe.
Prescribing data are also used to encourage good prac-
tice. For instance, in Scotland, the Scottish Antimicrobial
Prescribing Group encourages practitioners to continue
their good prescribing behaviour, on the assumption that
low antibiotic prescribing and low infection rates equate
to good practice, as explained by this interviewee:
“At board level … when you see somebody is good
and gives you a gold star that says your performance
is really good, your data is really good, it encourages
you to do more.” (Infectious Disease Physician).
Furthermore, one respondent felt that one of the plat-
forms for presenting data in England (the Fingertips Por-
tal) provided clinicians with sufficient guidance and
tools for appropriate prescribing, and had been used as
part of stewardship interventions to reduce prescribing.
However, a number of respondents at national level
identified limitations of the current prescribing data sys-
tems. For example, the data collection process can be la-
borious (a similar limitation was identified by
respondents at local level in secondary care).
Interviewees identified a gap in relation to private sec-
tor medical prescribing data and internet prescribing
data, in particular, as one put it:
“We do have a small amount of independent sector
prescribing that’s collated by Quintiles IMS … But
we have no assessment of what the high street is de-
livering essentially. We have no assessment about
what’s going on in the internet … And internet pre-
scribing as a whole and many of those it’s going to
be ... will be very difficult to determine because many
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of the providers are outside England and the UK.”
(Policy Official)
A gap was also identified in relation to private prescrib-
ing by some specialists, such as dermatologists, and by
dentists, as well as veterinarians.
The absence of an accepted definition of “appropriate
prescribing” also made it difficult to measure improve-
ment as this official remarked:
“How are we actually going to measure improve-
ments in appropriateness of prescribing? We can
look at decreased prescribing, we can look at changes
in patterns of resistance, but we can’t actually meas-
ure appropriate prescribing. Unless somebody’s come
up with some novel way of doing it, but we don’t
have it.” (Policy Official)
In addition to the limitations above, another respondent
cast doubt on whether the provision of prescribing data,
however robust, would make a difference to prescribing
behaviour:
“ … It’s really hard to say whether any of it makes
any difference, I’m not entirely sure, if you were to
ask any GP, that they would know what their pre-
scribing is like, I don’t think any of them would
probably be under any illusion about what they’re
doing … ” (Pharmacist at Health Board)
The two wishes frequently expressed by national users
of prescribing data were electronic prescribing in sec-
ondary care (see above) and closer integration with ani-
mal health and agriculture counterparts:
“We don’t really have formal connections with veter-
inary, other than in certain research bits … in terms
of veterinary medicine how much antimicrobial is
being used, be that sales data, be that consumption
geographically … I’m sure there are compounds that
are being used in horticulture that are similar to hu-
man antimicrobials and antifungals, in particular,
that may be having an issue for us further down the
line. If we could capture all of that data” (Consult-
ant Microbiologist with a role in national policy)
Resistance data
Primary care
There was no consensus among the respondents regard-
ing the value of providing antimicrobial resistance data
in primary care. One GP reported using local sensitivity
data to inform her/his prescribing decisions for urinary
tract infections. However, other respondents suggested
that GPs would not be interested in receiving
surveillance data on AMR, suggesting that this may be
related to the excessive volume of information they
already receive as this pharmacist noted:
“ … GPs, I don’t think would have any interest in
[surveillance data] whatsoever, to be honest … I
don’t think so … Secondary care is, most definitely.
They rely on it heavily. I think GPs get so inundated
with information that to start giving them surveil-
lance data, it’s something that just goes straight in
the bin, straight in delete, I’m afraid. It’s interesting,
but it’s not something that’s going to really change
much, I don’t think. They need to be told what to do.
I know that’s almost a nanny state or whatever, but
that’s what they want. They want, “This patient has
this condition, this is what you give.” (Pharmacist at
Health Board)
There was also a concern that some of the data available
on resistance and IPC (for example, the Clostridium dif-
ficile [C. diff] database) were not being utilised, and
therefore were not contributing to new understanding or
better identification of cases of healthcare-associated in-
fections. Finally, one respondent noted a lack of compli-
ance by certain bodies whose involvement was needed
to produce good data. The following quote from a com-
munity nurse related to GP practices:
“ … We have a problem, a current problem with the
LMC [Local Medical Committee] advising GP prac-
tices that we need patient consent before they’ll share
any information but I ask for anonymised informa-
tion and I don’t need to know anything about the
patient and under Section 251, I need to know that
information purely for education and patient safety
because it’s a disease, C. diff is something that can
be spread. But the LMC have decided that no”
(Community Liaison Nurse)
However, a contrary view was expressed to the perceived
“information overload” described above, in that some
primary care users of resistance/IPC data suggested that
the provision of easily accessible and timely information
on emerging resistance patterns (that could influence
prescribing decisions) was an area for improvement in
primary care, as seen in this quotation:
“ … it would be nice to, if there was an easily access-
ible table to say, in [geographic location], or in the
[trust name] in [geographic location], the majority of
UTIs are … whatever, or whatever, E. coli [Escheri-
chia coli], and the first line drugs are this, and pat-
terns resistance are increasing in this, this and this –
you would like to have something like that, that’d be
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very easy to use, but like the guidelines, where you
can check it up online if you’re interested, and
maybe if it were updated, say, annually, would be
brilliant; quarterly would be even better, if you could
do something like that there, it’d be nice … ” (Gen-
eral Practitioner)
Information currently available on platforms such as
Fingertips is not at the level of detail and timeliness to
meet these needs.
Secondary care
IPC data produced in hospitals are used in quality im-
provement audits, and are, in certain instances, helpful
in identifying links and patterns that are acted on to pre-
vent future outbreaks of infections, when the necessary
resources and capabilities are available. However, one
view expressed was that there were too many data to sift
through to obtain the information required:
“So we are constantly drowning in data stuff coming
in reports … What we absolutely struggle with and
we still struggle with is to get the key bits of data
that we need” (IPC Nurse)
Three of the limitations of IPC and resistance data iden-
tified by respondents echoed similar limitations noted
earlier in relation to prescribing data. These related to
the format in which data are presented; the opportunity
cost associated with collecting these data; and the gaps
in the data. The two quotes below illustrate the views in
relation to format and opportunity cost, respectively:
“ … [Organisation name] do a lot of epidemiology
for health boards in [geographic location], which is
great, but again they send these very complex reports
with, you know, all sorts of stuff on which is great for
epidemiologists but I’m really not sure that your job-
bing GP, junior doc, registrar, staff nurse, can make
head nor tail of a load of box and whisker plots … ”
(Senior IPC Nurse)
“ … why are we spending all our time doing it when,
actually, we know the lessons to learn? Let’s not
bother doing it and focus our efforts on reducing
gram negatives … ” (Lead Nurse for IPC)
A further limitation identified in relation to resistance/
IPC data was the absence of data on community carriage
levels, as shown in this quote:
“ … my worry there is that there’s just a lot of the
stuff out there, very little strong data on what the
community carriage rates are, and the more you
look, the more you’ll find … ” (Medical Director of
Trust)
There were also doubts expressed over the accuracy of
data available on Fingertips in England and the lack of
adjustment for the case mix of patients treated in differ-
ent hospitals.
Respondents discussed several priority areas for devel-
oping resistance data systems in secondary care in the
future. One respondent asked for more detailed labora-
tory reports than are currently produced, including in-
formation on susceptibility of microorganisms to a wider
range of antibiotics, to give clinicians greater freedom
when deciding on the most appropriate antibiotic to pre-
scribe. Another respondent expressed a desire for access
to warning systems to issue alerts regarding healthcare
associated infections:
“Warning systems would be good, so that if you have
... if you’re talking about colonisations of MRSA
[Methicillin-resistant Staphylococcus aureus], for ex-
ample, what would be the expected number in a
given area, so that you know you can actually set
warning limits for individual wards … ” (IPC Nurse)
Automating the methods of entering data into systems,
to overcome the time spent currently in making submis-
sions to national data systems, and ensuring that second-
ary care staff are allocated sufficient time to collect data,
were also significant issues. However, there was no
agreement regarding the benefit to hospital staff of re-
ceiving information on resistance and prescribing in the
community.
National level
A range of uses were identified for resistance data at na-
tional level. Firstly, data are used in research and this
can help to raise awareness when picked up by the
media. Resistance data can also be used to inform policy
as identified by this official:
“ … We know, for example, that about 30% of people
going into hospital from care homes are carrying
MRSA; they’re colonised with MRSA. You only really
know that from surveillance, and so that can inform
your policy on screening in patients for MRSA and
for decolonisation … that is really part of your evi-
dence base for new interventions” (Policy Official)
Related to the above, resistance data help service pro-
viders and commissioners plan services and react to
emerging trends, and enable them to alert the public to
take precautions during outbreaks, as explained by this
interviewee:
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“ … it’s there for the use of healthcare professionals
to try and pre-empt what’s going to come in the door
of casualty. So, you know in the summertime, you’re
going to get more food poisoning and D&V [diar-
rhoea and vomiting] type illnesses coming through,
but also then it lets the general public know that
there might be something circulating … ” (Consult-
ant Microbiologist)
However, one view expressed by an official at Health
Protection Scotland was that it was not necessarily help-
ful to provide the details of the sensitivities of microor-
ganisms associated with local outbreaks to national level
officials, as there is no need to act in the majority of
these instances, and it would be more prudent to let the
disease take its natural course than try to intervene in all
local outbreaks.
Generally, it was felt that the UK was in a much stron-
ger position with regard to data generation now than at
the launch of the Strategy in 2013. However, there were
limitations identified with resistance/ IPC data at the na-
tional level. The first was related to negative microbiol-
ogy test results often not being reported, shown in this
quote:
“ … we don’t know who gets samples sent so, and
that’s quite important because we don’t know the
positive predictive value of samples and we don’t
understand sort of who is getting tested and are the
right people getting tested so, because we don’t have
the negative results.” (Policy Official)
Additionally, clinical guidelines do not support testing in
all instances:
“ … the guidelines at the moment nationally, and in
many cases internationally, recommended that the
first episode of infection doesn’t have a urine sent,
you just treat based on empiric guidance.” (Policy
Official)
The second gap was in relation to the limited dissemin-
ation of the results of point of care tests that report on
the susceptibility of microorganisms to antibiotics, as
shown by this interviewee:
“ … And increasingly in the era of modern analyt-
ics, we don’t have any point of care testing results,
the results that are done on that … And that
again is quite important because increasingly
people are tested for things like carbapenems pro-
ducing bacteria by molecular methods rather than
by traditional susceptibility testing.” (Policy
official)
This could suggest that the quality of surveillance sys-
tems may deteriorate in the future if they do not incorp-
orate the results of rapid diagnostic tests, as their use
increases.
The final gap was the absence of reporting of vaccina-
tions (other than ‘flu vaccinations) and cases of sepsis
alongside other indicators in England. Confidentiality
was raised as a challenge when reporting a potentially
small number of cases without breaching the relevant
data protection legislation.
Respondents identified four main areas for improve-
ment of the national level resistance/ IPC data.
Firstly, an informant identified a benefit in transfer-
ring all data to one place, which would enable types
of data analysis that would not be possible otherwise,
acknowledging that this might not be permitted due
to research and data governance restrictions. Sec-
ondly, both positive and negative cases should be re-
ported through surveillance reporting networks to
give a more complete picture. Another informant reit-
erated the need for e-prescribing at all levels of care
and sentinel surveillance programmes at national level
for key drug-bug combinations that are expected to
present challenges in the future.
Thirdly, there was need to obtain a better understand-
ing of AMR in the environment, as part of a “One
Health” Approach as explained by this expert:
“ … In [geographic location], we don’t have a lot of
carbapenemase producers or at least we haven’t de-
tected a lot of carbapenemase producers, but we
don’t know what’s sitting out in the community and
it would be nice to get surveillance cultures. That’s
where One Health can come in. Is it worthwhile go-
ing down the lines of sampling sewage and things
like that to look for the things that are coming up
from human health, because we don’t know what’s
out there? (Consultant Microbiologist)
Finally, it was suggested that the development of “in-
telligent systems” could help guide prescribers and
introduce helpful variation in prescribing patterns de-
signed to limit the emergence of resistance. The fol-
lowing quote illustrates how such a system could
operate:
“ … you have data to say Mrs Bloggs comes in
and she’s got a UTI. You want to treat her and
the system will say she’s had these antibiotics be-
fore, this has been the resistance patterns, it
would randomly generate an antibiotic. That
would be the preferred process so it gets diversity
built into the system.” (Consultant Pharmacist in
Antimicrobials)
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Discussion
Main findings
Health care professionals in the UK perceive antimicro-
bial use and resistance data provided by surveillance sys-
tems as helpful in a number of ways. However, some
respondents were sceptical about the benefits for reasons
that relate to the data themselves (including the way
they are presented) and the overall system in which cli-
nicians operate.
First, several gaps were identified in the coverage of
current antimicrobial utilisation surveillance systems.
The gap in relation to data on private healthcare practice
and internet prescribing concurs with the findings of the
mapping exercise of existing systems that we conducted
as part of this research [10]. The gap in the information
available on prescribing in secondary care was attributed
to the fact that not all NHS Trusts in the UK were using
e-prescribing systems. A survey conducted in 2017 sug-
gested that 58% of Trusts in England did not have an ad-
vanced e-prescribing system in place [14]. The new UK
National Action Plan [9] has identified the introduction
of e-prescribing as part of electronic health records as
one of its goals to reach by 2025. However, whilst invest-
ing in e-prescribing in secondary care is expected to im-
prove the quality and ease of accessing data on
prescribing, and may aid antimicrobial stewardship ini-
tiatives, the introduction of such systems can be costly,
with the investment not always translating into im-
proved productivity, a phenomenon commonly referred
to as the “IT Productivity paradox” [15]. The research
evidence for the benefits of e-prescribing is limited but a
recent review looking at its wider impact in secondary
care in the UK concluded that, overall, it had resulted in
improved patient safety [16]. An important factor in this
relates to whether electronic prescribing operates as a
stand-alone system, or a modular system integrated with
other aspects of care. Although the latter can be more
convenient for users, interfacing with other systems can
be even more challenging to implement [17].
Second, there is need for an agreed definition of “ap-
propriate prescribing” in relation to the use of antibi-
otics. Whilst this was highlighted by more than one
respondent, ensuring that clinicians follow guidelines on
appropriate prescribing is not a straightforward process
[18] and may lead to clinicians feeling that they are be-
ing “micro-managed”. Careful benchmarking between
comparable services with comparable patient popula-
tions (if available) might overcome scepticism or
opposition.
Third, the risk of healthcare professionals under-
prescribing antibiotics has been identified in published
literature as a potential danger associated with the intro-
duction of prescribing guidelines [19]. However, there is
no published research that has demonstrated an
association between the provision of publicly available
data on prescribing rates of professionals and under-
prescribing of medications. This is an area that requires
further research.
Fourth, respondents identified the importance of sys-
tems that not only facilitate entering and processing data
but also present data in an accessible format. The US
Centers for Disease Control and Prevention (CDC) iden-
tified “simplicity” as one of the nine attributes for asses-
sing the performance of a health surveillance system
[20]. By that, CDC included aspects such as the methods
for analysing and disseminating the data, the time spent
on preparing the data for dissemination, and the time re-
quired to maintain the system. A consideration of the
extent to which UK systems meet the criterion of simpli-
city is beyond the remit of this paper but will be ad-
dressed in a separate publication. There is potentially
also a greater role for training at the local level on how
to collect, synthesise and interpret surveillance data, as
currently there may be a risk of over-reliance on the ex-
pertise of a few individuals who have acquired the neces-
sary skills, and who might leave a vacuum when they
move to another organisation. This is an area for further
investigation as part of workforce planning.
Finally, comparing the surveillance systems and plat-
forms that are available with respondents’ awareness of
these systems, it is evident that there is a mismatch be-
tween the two. This could be explained in part by the
fast pace at which these systems (especially the Finger-
tips Portal) are developing. There is a need to raise
awareness of the data systems and outputs already avail-
able to stakeholders in each country of the UK, and how
they can be used locally, which could be achieved
through better cascading of information and reports to
potential users.
Limitations
One limitation of this study is that we did not interview
data analysts whose role is to process data and present it
to policy makers and clinicians. Their views could differ
from other users of data. Another limitation was that we
did not interview representatives of some non-medical
prescribers, such as dentists, whose access to data differs
from that of doctors and varies across the four countries
of the UK [10].
Conclusions
We recommend that further efforts be made to raise
awareness of the data platforms that are available to health
care professionals in different settings and their potential
value, and to ensure that these systems are more easily ac-
cessible. Additionally, any skills gaps at local level in how
to manipulate and use the data that are currently available
need to be identified and addressed, potentially requiring
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improvement in support and education relating to collect-
ing, analysing and using AMR data.
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